[article] 
inLabAnimal-Europe > 02/16 (février 2016) . - p. 18-27

Titre :	Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats
Type de document :	texte imprimé
Auteurs :	Alan Cowan, Auteur
Année de publication :	2016
Article en page(s) :	p. 18-27
Langues :	Anglais (eng)
Mots-clés :	Analgesics, Opioid/adverse effects*  Animals  Body Weight/drug effects  Buprenorphine/adverse effects*  Delayed-Action Preparations  Dose-Response Relationship, Drug  Female  Injections, Subcutaneous  Male  Nausea/chemically induced  Postoperative Period  Rats, Inbred F344  Analgesics, Opioid  Buprenorphine
Résumé :	Abstract Extended-release buprenorphine is an effective analgesic in laboratory animals, and its safety has been established in mice but not in rats. The authors used a target animal safety trial to evaluate the safety of extended-release buprenorphine in rats. Fischer 344 rats received post-surgical subcutaneous injections of 1.3 mg, 3.9 mg or 6.5 mg buprenorphine per kg body weight (two times, six times or ten times the intended dose, respectively), and their body weight, clinical signs and symptoms, clinical pathology and histopathology were monitored for 4 d. Body weight was not significantly different in rats that received buprenorphine compared with control rats. Signs of nausea-related behavior were observed in 25% of the rats treated with buprenorphine. Clinical pathology results for all rats were normal, and gross and microscopic histopathology examinations identified no substantial abnormalities, suggesting that this behavior was of minor consequence. Other adverse events previously reported to occur with opiate therapy, including weight loss and dermal lesions at drug injection sites, were not observed in this study. The results of this study show that post-surgical administration of an extended-release buprenorphine product is safe in Fischer 344 rats and does not necessarily cause substantial adverse effects, confirming that opiate therapy is a viable choice in laboratory animal medicine.
Permalink :	./index.php?lvl=notice_display&id=66490

[article] Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats [texte imprimé] / Alan Cowan, Auteur . - 2016 . - p. 18-27.
Langues : Anglais (eng)
in LabAnimal-Europe > 02/16 (février 2016) . - p. 18-27

Mots-clés :	Analgesics, Opioid/adverse effects*  Animals  Body Weight/drug effects  Buprenorphine/adverse effects*  Delayed-Action Preparations  Dose-Response Relationship, Drug  Female  Injections, Subcutaneous  Male  Nausea/chemically induced  Postoperative Period  Rats, Inbred F344  Analgesics, Opioid  Buprenorphine
Résumé :	Abstract Extended-release buprenorphine is an effective analgesic in laboratory animals, and its safety has been established in mice but not in rats. The authors used a target animal safety trial to evaluate the safety of extended-release buprenorphine in rats. Fischer 344 rats received post-surgical subcutaneous injections of 1.3 mg, 3.9 mg or 6.5 mg buprenorphine per kg body weight (two times, six times or ten times the intended dose, respectively), and their body weight, clinical signs and symptoms, clinical pathology and histopathology were monitored for 4 d. Body weight was not significantly different in rats that received buprenorphine compared with control rats. Signs of nausea-related behavior were observed in 25% of the rats treated with buprenorphine. Clinical pathology results for all rats were normal, and gross and microscopic histopathology examinations identified no substantial abnormalities, suggesting that this behavior was of minor consequence. Other adverse events previously reported to occur with opiate therapy, including weight loss and dermal lesions at drug injection sites, were not observed in this study. The results of this study show that post-surgical administration of an extended-release buprenorphine product is safe in Fischer 344 rats and does not necessarily cause substantial adverse effects, confirming that opiate therapy is a viable choice in laboratory animal medicine.
Permalink :	./index.php?lvl=notice_display&id=66490